Biotech stocks pin bounce back hopes on M&A boost
Plunging valuations have made biotech companies tempting acquisition targets for cash-rich Big Pharma and a flurry of deals is just what the battered sector needs to turn a corner.
New Search
If you are not happy with the results below please do another search
Search
50 search results for:
Blood pressure drug terazosin shows promise in ALS treatment
/in R&D, Therapeutics“Our work shows that terazosin is protective of motor neuron cell death in multiple models of MND [motor neuron disease], making it an exciting new potential therapy,” says Helena Chaytow, the study’s first author and senior postdoctoral researcher at the University of Edinburgh.
Got milk? It may do the microbiome – and patients – good
/in R&D, TherapeuticsIn a first, Prolacta Bioscience recently published a proof of concept study showing that components of human breast milk can treat the adult microbiome without antibiotics.
Abbott to add 1,000 jobs in $450 million Irish investment
/in Business, TherapeuticsConfirming the $450 million investment, Abbott’s senior vice-president for diabetes care, Jared Watkin, told the Irish Times that choosing Ireland for its increased production of devices that monitor glucose levels made strategic sense.
J&J to end global sales of talc-based baby powder
/in Marketing & AdvertisingJohnson & Johnson will stop selling talc-based baby powder globally in 2023, the drugmaker said on Thursday, more than two years after it ended U.S. sales of a product that drew thousands of consumer safety lawsuits.
Roche announces U.S. FDA approval of Xofluza to treat influenza in children aged five years and older
/in TherapeuticsXofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the United States for children as young as five years of age. The FDA also approved the drug to prevent influenza in children aged five years and older following contact with an infected person.
Novartis reports Zolgensma caused two deaths from liver failure
/in TherapeuticsThe two fatal cases of acute liver failure took place in Russia and Kazakhstan after 5 to 6 weeks of Zolgensma infusion and about 1-10 days following the initiation of corticosteroid taper, according to the company.
Senate Finance Committee looks at Amgen taxes, widening drugmaker probe
/in TherapeuticsThe U.S. Senate Finance Committee is widening its investigation into the tax practices of U.S. drugmakers to include Amgen Inc (AMGN.O), according to a letter sent on Thursday by the committee’s chairman, Senator Ron Wyden.
Greater Than One names new executive creative director
/in Marketing & AdvertisingGreater Than One, a privately held agency focused on healthcare, announced that Mindy Telmer has been appointed executive creative director, EVP. Telmer will be the creative voice of the agency, responsible for providing Greater Than One clients with strategic creative direction and oversight from inception through execution. Telmer will report directly to Matthew Howes, president of Greater Than One.
Biogen cuts costs by $1B as industry braves economic instability
/in Business, TherapeuticsWhile the economy expands and contracts, the biopharma industry follows, and many life science companies are announcing both layoffs and expansions.
